OR Royalties (NYSE:OR) Downgraded by Wall Street Zen to Buy

Wall Street Zen downgraded shares of OR Royalties (NYSE:OR) from a strong-buy rating to a buy rating in a research report released on Sunday morning.

A number of other equities research analysts also recently weighed in on OR. Jefferies Financial Group restated a “hold” rating and issued a $38.00 price target on shares of OR Royalties in a research note on Sunday, December 7th. Raymond James Financial raised shares of OR Royalties from a “market perform” rating to an “outperform” rating and set a $41.00 price objective for the company in a research note on Thursday, November 6th. Weiss Ratings restated a “buy (b)” rating on shares of OR Royalties in a research report on Monday, December 29th. Scotiabank cut shares of OR Royalties from an “outperform” rating to a “sector perform” rating and boosted their target price for the stock from $33.00 to $41.00 in a research note on Thursday, October 23rd. Finally, Canaccord Genuity Group upgraded shares of OR Royalties from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.75.

OR Royalties Stock Performance

Shares of OR stock opened at $38.57 on Friday. OR Royalties has a fifty-two week low of $17.55 and a fifty-two week high of $42.25. The stock’s fifty day moving average price is $34.56 and its two-hundred day moving average price is $33.12. The company has a market cap of $7.22 billion, a PE ratio of 48.83 and a beta of 0.78.

OR Royalties (NYSE:OR) last announced its quarterly earnings data on Wednesday, November 5th. The basic materials company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.03. The business had revenue of $71.63 million during the quarter, compared to the consensus estimate of $53.85 million. OR Royalties had a return on equity of 10.67% and a net margin of 60.72%. On average, equities analysts predict that OR Royalties will post 0.62 EPS for the current fiscal year.

OR Royalties Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Wednesday, December 31st will be paid a dividend of $0.055 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $0.22 annualized dividend and a dividend yield of 0.6%. OR Royalties’s dividend payout ratio (DPR) is presently 27.85%.

Institutional Trading of OR Royalties

Several institutional investors have recently modified their holdings of OR. Caitlin John LLC bought a new position in OR Royalties during the 3rd quarter worth $78,000. Eagle Global Advisors LLC acquired a new stake in shares of OR Royalties in the third quarter valued at about $206,000. Merit Financial Group LLC bought a new position in shares of OR Royalties during the third quarter worth about $215,000. Flow Traders U.S. LLC bought a new position in shares of OR Royalties during the third quarter worth about $217,000. Finally, Moors & Cabot Inc. acquired a new position in shares of OR Royalties in the third quarter worth approximately $220,000. Institutional investors own 68.52% of the company’s stock.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.